J&J/Bayer’s Once-Daily Rivaroxaban Superior To Lovenox In Phase III Trial

 
• By Pamela Taulbee

J&J/Bayer are on track to file for venous thromboembolism indication in U.S. in 2008, while Bristol/Pfizer’s apixaban NDA filing is slated for second half of 2009, firms tell “The Pink Sheet” DAILY.

More from Archive

More from Pink Sheet